Red flags with SNSS are six fold. First their drug does not work as a single agent. Second their study is 2 drugs in combination versus 1 which introduces statistical complexity and makes it more difficult to define the true activity of the drug. Third, in view of this complexity, it may have been prudent to secure a SPA which they did not achieve. Fourth, data inconsistencies between phase 2 and phase 3. Fifth, at interim results they were directed by the DSMB to increase the size of their study which suggests only marginal improvement over the control arm. Sixth, older patients do not do well on Cytarabine combinations.
Sentiment: Strong Sell
Not here to gloat but I warned you all. Switch to CYCC before it's too late. CYCC has RMDS pathway news coming at ASCO and much more after that. Whatever you have lost here, you will get it all back in CYCC. Study the data and the numbers. GL
Sentiment: Strong Buy
then why no insider selling ? how come 96 % of the float is owned by institutions and mutual funds ?
not exactly a retail muppet pump according to those facts - oh wait, you and your pals are pumping CYCC. that explains it.
What is not credible?, these are the facts! Many here will be very let down as more and similar data is written about. There are many problems with SNSS, While Life favors CYCC, he has never misquoted facts. Maybe some of the posters here really don't understand the stock they bought, SNSS's drug pipeline VS other companies. SNSS's drug has limited usage and was tested on a less risky population than CYCC's drug. Sure you could make some money during manufacturing, but once more news of CYCC's drug pipeline is released, SNSS will not survive.